ArticleVirology journal2026
Evaluation of the antiviral effect of casein nanoparticles (CNP) loaded with Plantago major extract (PME-CNP) on herpes simplex virus.
Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHerpes simplex virus (HSV) infections remain a global health challenge due to their persistence, limited treatment options and drug resistance. In this study, the antiviral potential of Plantago major extract (PME) encapsulated in casein nanoparticles (CNPs) against HSV-1 was investigated.
methodsPME was extracted with ethanol by Soxhlet extraction, concentrated and analyzed by gas chromatography-mass spectrometry. PME-loaded CNPs (PME-CNPs) were prepared by cross-linking casein with calcium chloride and subsequent centrifugation. The nanoparticles were characterized in terms of size, morphology (dynamic light scattering, scanning electron microscopy), chemical interactions (Fourier transform infrared spectroscopy), crystallinity (X-ray diffraction), thermal stability (differential scanning calorimetry) and encapsulation efficiency (UV-visible spectroscopy). The in vitro release kinetics were investigated using dialysis. Antiviral activity was tested in Vero cells using cytotoxicity assays, viral titration (50% Tissue Culture Infectious Dose, TCID₅₀) and three treatment modes: virucidal (pre-treatment of the virus), prophylactic (pre-treatment of the cells) and therapeutic (post-infection). Statistical significance (p < 0.05) was determined using ANOVA.
resultsThe PME-CNPs exhibited uniform size (118.6 nm), stability (zeta potential: −19.4 mV) and spherical morphology. The encapsulation efficiency was 82.1%, with sustained release (76.8% over 2 h, first-order kinetics). PME-CNPs showed lower cytotoxicity than free PME. Antiviral assays showed significant inhibition of HSV-1: virucidal (2.7-log reduction), prophylactic (1.2-log) and therapeutic (1.9-log at 1 h post-infection), outperforming free PME (p < 0.05). Early post-infection treatment indicates inhibition of viral entry/replication.
conclusionsPME-CNPs improve bioavailability, sustain release, and enhance antiviral efficacy against HSV-1, supporting their potential as a plant-based nanotherapeutic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.